The incidence of ILD caused by m-TOR inhibitors has been reported to be approximately 0.4% to 10%, and the mechanism may involve direct cytotoxicity, immune-mediated inflammatory response, and vascular endothelial damage (25, 26). Here, MTOR is linked to interstitial lung disease.